Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma

Mahadevan, Anand; Dagoglu, Nergiz; Mancias, Joseph; Raven, Kristin; Khwaja, Khalid; Tseng, Jennifer F; Ng, Kimmie; Enzinger, Peter; Miksad, Rebecca; Bullock, Andrea; Evenson, Amy

doi:10.7150/jca.13032



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2015; 6(11):1099-1104. doi:10.7150/jca.13032 This issue Cite

Research Paper

Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma

Anand Mahadevan¹, Nergiz Dagoglu¹, Joseph Mancias¹, Kristin Raven², Khalid Khwaja², Jennifer F Tseng², Kimmie Ng³, Peter Enzinger³, Rebecca Miksad⁴, Andrea Bullock⁴, Amy Evenson^2✉

1. Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts, USA
2. Department of Surgery, Harvard Medical School, Boston, Massachusetts, USA
3. Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
4. Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA

Citation:

Mahadevan A, Dagoglu N, Mancias J, Raven K, Khwaja K, Tseng JF, Ng K, Enzinger P, Miksad R, Bullock A, Evenson A. Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma. J Cancer 2015; 6(11):1099-1104. doi:10.7150/jca.13032. https://www.jcancer.org/v06p1099.htm

Other styles

Abstract

Background: Unresectable intrahepatic and hilar cholangiocarcinomas carry a dismal prognosis. Systemic chemotherapy and conventional external beam radiation and brachytherapy have been used with limited success. We explored the use of stereotactic body radiotherapy (SBRT) for these patients.

Methods: Patients with unresectable intrahepatic or hilar cholangiocarcinoma or those with positive margins were included in this study. Systemic therapy was used at the discretion of the medical oncologist. The Cyberknife^TMstereotactic body radiotherapy system used to treat these patients. Patients were treated with three daily fractions. Clinical and radiological follow-up were performed every three months.

Results: 34 patients (16 male and 18 female) with 42 lesions were included in this study. There were 32 unresectable tumors and two patients with resected tumors with positive margins. The median SBRT dose was 30Gy in three fractions. The median follow-up was 38 months (range 8-71 months). The actuarial local control rate was 79%. The median overall survival was 17 months and the median progression free survival was ten months. There were four Grade III toxicities (12%), including duodenal ulceration, cholangitis and liver abscess.

Conclusions: SBRT is an effective and reasonably safe local therapy option for unresectable intrahepatic or hilar cholangiocarcinoma.

Keywords: stereotactic body radiotherapy, cholangiocarcinomas

Citation styles

APA

Mahadevan, A., Dagoglu, N., Mancias, J., Raven, K., Khwaja, K., Tseng, J.F., Ng, K., Enzinger, P., Miksad, R., Bullock, A., Evenson, A. (2015). Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma. Journal of Cancer, 6(11), 1099-1104. https://doi.org/10.7150/jca.13032.

ACS

Mahadevan, A.; Dagoglu, N.; Mancias, J.; Raven, K.; Khwaja, K.; Tseng, J.F.; Ng, K.; Enzinger, P.; Miksad, R.; Bullock, A.; Evenson, A. Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma. J. Cancer 2015, 6 (11), 1099-1104. DOI: 10.7150/jca.13032.

NLM

CSE

Mahadevan A, Dagoglu N, Mancias J, Raven K, Khwaja K, Tseng JF, Ng K, Enzinger P, Miksad R, Bullock A, Evenson A. 2015. Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma. J Cancer. 6(11):1099-1104.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.